Mallinckrodt StrataGraft Skin Therapy Could Be The First RMAT-Designated Therapy Approved By US FDA
Executive Summary
The company presented positive data from a Phase III pivotal trial during the American Burn Association virtual annual meeting.
You may also be interested in...
Mallinckrodt Finds An Exit Door For Generics In Proposed Opioid Settlement
The company has reached a broad opioid settlement agreement in principle under which its specialty generics subsidiaries would file for Chapter 11 bankruptcy and Mallinckrodt's branded business would operate separately.
Keeping Track: US FDA's Rejection Of First RMAT BLA Blemishes Otherwise Positive Week Of Non-Oncology News
The latest non-oncology drug development news and highlights from our US FDA Performance Tracker.
Blueprint’s Evolution On Its Path To Financial Sustainability
Chief operating officer Christina Rossi talked to Scrip about the company’s new blockbuster-sized commercial opportunity for Ayvakit and the company’s next phase: financial sustainability.